A single-shot vaccine approach for the universal influenza A vaccine candidate M2e.
Where this comes from
- Record sourced from PubMed, PMID 35320040.
- Also identified by DOI 10.1073/pnas.2025607119 and PMC identifier 9060463.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
SignificanceAlthough the need for a universal influenza vaccine has long been recognized, only a handful of candidates have been identified so far, with even fewer advancing in the clinical pipeline. The 24-amino acid ectodomain of M2 protein (M2e) has been developed over the past two decades. However, M2e-based vaccine candidates have shortcomings, including the need for several administrations and the lack of sustained antibody titers over time. We report here a vaccine targeting strategy that has the potential to confer sustained and strong protection upon a single shot of a small amount of M2e antigen. The current COVID-19 pandemic has highlighted the importance of developing versatile, powerful platforms for the rapid deployment of vaccines against any incoming threat.
Medical subject headings
- COVID-19
- Influenza A virus
- Influenza Vaccines
- Influenza, Human
- Viral Matrix Proteins
- Viroporin Proteins